- A new study has revealed that West Virginia has the most GLP-1 users, with 24,217.07 GLP-1 prescriptions per 100,000 residents.
- Kentucky follows in second, with a GLP-1 user rate of 22,003.90 per 100,000 people.
- Hawaii has the lowest number of users, with 5,050.46 GLP-1 prescriptions per 100,000 residents.
Many Americans will be seeking out ways to manage and lose weight in 2026, with a newly launched Wegovy pill already seeing high uptake.
That’s why a new study has revealed the states with the highest number of GLP-1 users. GLP-1 drugs include Ozempic, Wegovy, and Mounjaro, and are used by many for weight loss.
The research, conducted by GLP-1 provider Nutrition NC, examined the prescription numbers for GLP-1 prescriptions dispensed in 2024, scaled to local populations to establish a prescription rate per 100,000 residents in each state.
West Virginia has the highest number of GLP-1 users, with 24,217.07 GLP-1 prescriptions dispensed per 100,000 residents. The number of GLP-1 prescriptions in 2024 reached 428,367, representing a 3.2% decrease from 2023.
Kentucky has the second-highest number of users, with 22,003.90 GLP-1 prescriptions dispensed per 100,000 residents in 2024. 1,009,621 prescriptions were dispensed in 2024, a 2.6% increase from 2023.
In third place is Louisiana, where 20,282.44 GLP-1 prescriptions per 100,000 residents were dispensed in 2024. In this state, a total of 932,543 GLP-1 prescriptions were dispensed, representing an 11.6% decrease.
Ranking fourth is Oklahoma, which recorded 19,504.89 GLP-1 prescriptions dispensed per 100,000 residents. Oklahoma saw a 16.8% increase in the number of GLP-1 prescriptions from 2023-2024, with 798,802 prescriptions dispensed in 2024.
Coming in fifth is Alabama, with 19,260.64 GLP-1 prescriptions dispensed per 100,000 residents. The number of GLP-1 prescriptions in this state rose slightly from 2023, by 0.4%, with a total of 993,406 dispensed in 2024.
Mississippi is in sixth place, with 18,745.96 GLP-1 prescriptions dispensed per 100,000 residents. In this state, the number of GLP-1 prescriptions dispensed in 2024 topped 551,702, an increase of 2.0% from 2023.
Next up is North Dakota, where 17,840.03 GLP-1 prescriptions were dispensed per 100,000 residents. 142,108 GLP-1 prescriptions were dispensed in 2024, representing a 20.8% increase from 2023.
Alaska ranks eighth, with 17,383.09 GLP-1 prescriptions dispensed per 100,000 residents in 2024. In this state, 128,658 GLP-1 prescriptions were dispensed in 2024, representing a 21.8% increase from 2023, the largest increase in this top ten listing.
In ninth place is Arkansas, with 17,346.00 GLP-1 prescriptions dispensed per 100,000 residents. 535,706 prescriptions were dispensed in 2024, a 1.4% decrease from 2023.
Finally, rounding off the top ten is Pennsylvania, with 17,131.12 GLP-1 prescriptions per 100,000 residents dispensed in 2024. 2,240,537 GLP-1 prescriptions were dispensed in 2024, an 8.8% increase from 2023.
On the other end of the scale, Hawaii has the lowest number of GLP-1 users, with 5,050 GLP-1 prescriptions dispensed per 100,000 residents. A total of 73,037 prescriptions were dispensed in 2024, a 21.0% increase from 2023.
The 10 states with the most GLP-1 prescriptions in 2024
| State | GLP-1 Prescriptions Dispensed in 2024 (Per 100,000 Residents) | Percentage Change (2023 to 2024) | |
| 1 | West Virginia | 24,217.07 | -3.2% |
| 2 | Kentucky | 22,003.90 | 2.6% |
| 3 | Louisiana | 20,282.44 | -11.6% |
| 4 | Oklahoma | 19,504.89 | 16.8% |
| 5 | Alabama | 19,260.64 | 0.4% |
| 6 | Mississippi | 18,745.96 | 2.0% |
| 7 | North Dakota | 17,840.03 | 20.8% |
| 8 | Alaska | 17,383.09 | 21.8% |
| 9 | Arkansas | 17,346.00 | -1.4% |
| 10 | Pennsylvania | 17,131.12 | 8.8% |
Commenting on the study, Natalie Mootz, CMO of Nutrition NC, said:
“It’s fascinating to see the varying rates of GLP-1 prescriptions across the country, highlighting the states where medications like Ozempic are most commonly used. With West Virginia leading the rankings, the differences may be due to a variety of factors, including healthcare access, lifestyle, and medical needs.
“As the conversation around GLP-1 medications continues, it’s important to consider the factors driving these trends. Understanding these patterns can help inform future discussions on public health and medical accessibility.”
